Augmentation of immune responses of pelvic lymph node lymphocytes in patients with cervical cancer by sizofiran.
Shimizu
Y
Y
Department of Gynecology, Cancer Institute Hopital, Tokyo.
Chen
J T
JT
Hirai
Y
Y
Nakayama
K
K
Hamada
T
T
Fujimoto
I
I
Hasumi
K
K
Masubuchi
K
K
D003602:Cytotoxicity, Immunologic; D005260:Female; D006025:Glycosaminoglycans / Q000494:pharmacology*; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D008198:Lymph Nodes / Q000276:immunology* / Q000473:pathology; D008214:Lymphocytes / Q000276:immunology* / Q000378:metabolism; D010388:Pelvis; D012566:Sizofiran / Q000494:pharmacology*; D002583:Uterine Cervical Neoplasms / Q000276:immunology*
D006025:Glycosaminoglycans; D007376:Interleukin-2; D012566:Sizofiran